References
- Peterson PK, Matzke G, Keane WF. Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 1987; 9: 604–12.
- Keller E, Jansen A, Petz K, Hoppeseyler G, Schollmeyer P. Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmac Ther 1984; 35: 208–13.
- Saha SK. Peritoneal lavage with metronidazole. Surg Gyncol Obstet 1985; 160: 335–8.
- Kaplan RA, Markman M, Lucas WE, Pfeifle C, Howell SB. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 1985; 78: 49–53.
- Hodler JE, Gaeazzi RL, Frey B, Rudhardt M, Seiler AJ. Pharmacokinetic of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications. Eur J Clin Pharmacol 1984; 26: 609–12.
- Johnson CA, Zimmerman SW, Reitberg DP, Whall TJ, Leggett JE, Craig WA. Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Che mother 1988; 32(1): 51–6.
- Torres IJ, Litterst CL, Guarino AM. Transport of model compounds across the peritoneal membrane in the rats. Pharmacology 1978; 17: 330–40.
- Schneider AL, Wacarda L, Klitzing EV, Kochen W, Hellenbrecht D. Experimental observations on peritoneal transport in rabbits. Kidney 1983; 24 (suppl 15): S. 89-S94.
- Maher JF, Casoetta M, Shea C, Hohnadel DC. Peritoneal dialysis in rabbits. A study of transperitoneal theophylline flux and peritoneal permeability. Nephron 1978; 20: 18–23.
- Cowlishaw MG, Sharman JR. Liquid-chromatographic assay of cefoperazone from plasma and bile. Clin Chem 1986; 32: 894.
- Bartel IJ, Hussey JL, Shrago E. Effect of dialysis on serum carnitine, free fatty acids and triglyceride level in man and the rat. Metabolism 1982; 31(9): 944–47.
- Balant L, Dayer P, Rudhart M, Allaz A, Fabre J. Cefoperazone: Pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Therap 1980; 3: 50–59.
- Fabre J, Rudhardt M, Dayer P, Trimble ER, Male PJ. The effects of biliary obstruction on excretion of cefoperazone in the rats. Arzneimittelforschung 1984; 34(7): 789–91.
- Hayashi T, Watanabe Y, Kumano K, et al. Pharmacokinetic studies on the concomitant administration of piperacillin and cefazolin, and piperacillin and cefoperazone in rabbits. J Antibiot 1986; 39: 699–712.
- Craig WA, Gerber AV. Pharmacokinetic of cefoperazone. Drugs 1981; 22 (supple 1): 35–45.
- Pattinson NR, Cowlishaw M, Chapman BA. Biliary secretion of cefoperazone and its relationship with bile acid transport in the rat. Biochem Int 1987; 15(3): 653–58.
- Camaggi CM, Stracchi E, Costanti B, Beghelli P, Ferrari P, Pannuti F. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer. Cancer Chemother Pharmacol 1985; 14: 232–34.